Economic impact of self-administered versus clinic-administered immunoglobulin G therapy

Self-administered subcutaneous immunoglobulin G (SCIg) reduces nursing time and eliminates the need for treatment at ambulatory care clinics, as compared with clinic-based intravenously administered IgG (IVIg), and are therapeutically equivalent. Using administrative health data in Alberta, this population-based cohort study examined the costs of IgG administration (SCIg versus IVIg) in Alberta between 2012 – 2019. Authors found that self-administered SCIg is substantially less costly from a health care payer perspective in Canada. Within this type of health system, switching to self-administered SCIg has the potential to reduce overall health care costs, lessen nursing burden, and may increase clinic-based capacity for others.